Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Samsung Electronics | Eli Lilly and Company | Walmart | |
|---|---|---|---|
| Moat rating | narrow Samsung leads three of its four principal markets — Q1 2026 DRAM revenue share 38.5% ($37.32B, TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), Q1 2026 NAND share 31.6% ($13.51B, TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html), and #1 in Q2 2026 smartphones at 24% (Counterpoint via Android Authority, https://www.androidauthority.com/counterpoint-research-q2-2026-smartphone-shipment-report-3686931/) — but the moat is narrow, not wide: memory economics are violently cyclical (industry DRAM revenue swung +81% QoQ on contract-price spikes per the same TrendForce release), SK hynix holds the highest HBM bit-shipment mix among the top three (same release), and foundry trails TSMC 6.5% vs ~72% share (TrendForce data via TelecomLead, https://telecomlead.com/semiconductor/global-foundry-market-hits-record-47-95-bn-in-q1-2026-as-ai-chip-demand-drives-growth-tsmc-expands-share-to-72-126247). | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow Graded on the Item 1A text this run could read from the FY2026 10-K, which is where the filing argues hardest against a wide band. It says "each of our segments competes for customers, employees, digital prominence, products and services" with local, regional, national and global physical, eCommerce and omnichannel retailers, social commerce platforms, wholesale club operators, retail intermediaries "and emerging agentic shopping tools and platforms," that "the omnichannel retail landscape is highly competitive and rapidly evolving, and the entry of new, well-funded competitors, or more rapid development of AI capabilities and agentic tools by these competitors ... may increase competitive pressures," and concedes that "for eCommerce and other internet-based businesses, newer or smaller businesses may be better able to innovate and compete with us" and that there "can be no assurance" Walmart can adopt AI "as quickly or effectively as our competitors." It also warns of retail consolidation producing rivals with "improved financial resources, improved access to merchandise, greater market penetration." The filing claims no market share, rank or scale advantage anywhere in the text available here, and its own competitive-landscape discussion sits in Item 1, which the cached read-through returned only as a cross-reference; a wider band would not be sourced. |
| Moat type | cost scale The durable advantage is manufacturing scale and capital intensity: the top three DRAM suppliers take roughly $8.97 of every $10 of industry revenue (Samsung 38.5% + SK hynix 28.8% + Micron 22.4% in Q1 2026 per TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), a structure sustained by multi-billion-dollar fab economics that has admitted no new large entrant in decades; Samsung is the largest-revenue producer in both DRAM and NAND (TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html). | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | cost scale What the readable text does describe as durable is physical and logistical scale rather than lock-in or IP. It says Walmart sources "from a wide variety of domestic and international suppliers," that global sourcing is "an important factor in our financial performance," and that finding suppliers able to supply "in the large volumes we may demand" is itself a challenge; it describes a network of stores, clubs and distribution and fulfillment centers in which "many products available for purchase online can be picked up by the customer or member at a local Walmart store or Sam's Club, which provides additional customer traffic at such stores and clubs"; and it lists "supply chain automation and enhancements" among the investments backing the strategy. The first competitive lever it names is "the prices at which we sell our merchandise." The filing offers no intangibles or switching-cost claim beyond noting that protection of its trademarks, copyrights, domain names, patents and trade secrets "may not be available in every jurisdiction." |
| Leadership | co leader Revenue leader in DRAM (38.5%) and NAND (31.6%) in Q1 2026 (TrendForce) and #1 in Q2 2026 smartphone shipments (Counterpoint), but not the leader where AI value concentrates: SK hynix has the highest HBM bit-shipment mix among the top three DRAM suppliers (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) and TSMC dominates foundry with ~72% share to Samsung's 6.5% (TrendForce via TelecomLead). | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader The 10-K text available this run asserts no rank or share for Walmart. The band reflects two things the filing does say: that its strategy is meant to let it "maintain or grow our overall market position" across segments that already compete at global scale, and that it does not describe itself as ahead in the channels that matter most to it - "for eCommerce and other internet-based businesses, newer or smaller businesses may be better able to innovate and compete with us," and on AI adoption "there can be no assurance that these investments will deliver the anticipated benefits, or that we will be able to adopt and leverage these technologies as quickly or effectively as our competitors." Treat this band as bounded by the missing Item 1 competition discussion, not as a measured position. |
| Pricing power | moderate Current pricing is extraordinary but cyclical, not structural: conventional DRAM contract prices rose roughly 93-98% QoQ in Q1 2026 (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) — shortage-driven commodity pricing that reverses in downcycles. The set-side shows the limit: Samsung's own MX (smartphone) division posted a KRW 0.7 trillion operating loss in Q2 2026 on elevated component costs (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak The filing names price first among the ways it competes - "we compete in a variety of ways, including the prices at which we sell our merchandise" - and states that higher supplier labour and material costs may "adversely impact product margins ... that we are unable, or choose not, to pass on to our customers." It adds that macro conditions can "change the mix of products we sell to any one or more markets with a lower average gross margin" and "result in slower inventory turnover and greater markdowns of inventory." In health and wellness the price is set by counterparties, not by Walmart: "a large majority of our retail pharmacy net sales are generated by filling prescriptions for which we receive payment through established contractual relationships with third-party payers and payment administrators, such as private insurers, governmental agencies and pharmacy benefit managers," exposing it to "reductions in the third-party reimbursement rates for drugs." |
| Summary | Samsung Electronics is the world's largest memory maker and a vertically integrated device company. In Q1 2026 it was #1 in DRAM (38.5% revenue share) and #1 in NAND (31.6%), and in Q2 2026 it retook #1 in global smartphones at 24% share. The AI-datacenter memory shortage produced record results: Q2 2026 company revenue of KRW 171.5 trillion and an all-time-high operating profit of KRW 89.5 trillion, with server memory reaching a record share of the sales mix and HBM4E samples shipped to major customers (Samsung Newsroom). The caveats that keep the moat narrow: the profit pool is a price cycle, not a structural annuity; SK hynix leads the highest-value HBM segment by bit-shipment mix; and Samsung Foundry, at 6.5% share versus TSMC's ~72%, remains a distant second in leading-edge logic despite expanding 2nm design wins. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | In the FY2026 10-K text readable this run, Walmart describes an "enterprise strategy, which combines traditional retail, membership models, marketplaces, financial services, health and wellness and other customer and business services into a series of interconnected assets to make it seamless for customers to interact with us," carried by stores, clubs and distribution and fulfillment centers that double as pickup and delivery nodes and by continuing investment in eCommerce, AI and supply chain automation. The filing sets its own limits on that: it calls the omnichannel landscape "highly competitive and rapidly evolving," warns that well-funded entrants and faster AI or agentic tooling by rivals may increase pressure, that smaller businesses may out-innovate it online, and that "a greater concentration of eCommerce sales, including increasing online grocery sales and the increasing role of AI-enabled platforms in product search, discovery, advertising and purchasing, could result in a reduction in the amount of traffic in our stores and clubs." On economics it concedes supplier cost increases it may be "unable, or choose not, to pass on to our customers," and it points investors to "advertising and other higher-margin initiatives (which are expected to help drive our operating income growth at a rate faster than net sales over the long term)" rather than to price. |
| Chain position | Upstream supplier of DRAM/HBM and NAND to the AI datacenter buildout (server memory at a record share of its Q2 2026 sales mix; HBM4E samples shipped to major customers) and a contract foundry, while simultaneously a downstream device maker (Galaxy) that consumes its own components (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | A retailer that also intermediates: it sells its own sourced merchandise, hosts third-party marketplace sellers for whom it may provide "fulfillment, inventory management, tax collection, payment processing, content," sells digital advertising against that traffic, dispenses prescriptions under PBM and payer contracts, and offers financial services "including through our digital channels, stores and clubs, as well as our OnePay fintech venture." |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. |